

---

## **BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)**

CAMBRIDGE, Mass. and BEIJING, China, September 11, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-1 antibody tislelizumab, its investigational BTK inhibitor zanubrutinib, and its investigational PARP inhibitor pamiparib, will be presented in seven oral presentations and four poster presentations at the 22<sup>nd</sup> Annual Meeting of the Chinese Society of Clinical Oncology (CSCO), taking place September 18-22, 2019 in Xiamen, China.

### **Oral Presentations:**

**Title:** **Tislelizumab in Chinese Patients with Non-Small Cell Lung Cancer (NSCLC) and Nasopharyngeal Carcinoma (NPC)**  
**Session:** Lung Cancer Session 1  
**Date:** Thursday, September 19  
**Time:** 11:20 – 11:25  
**Location:** Auditorium, Level 1  
**Presenter:** Qing Zhou, M.D., Ph.D., Guangdong Provincial People's Hospital

**Title:** **Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: Updated Follow-up Efficacy and Safety Results from a Phase 2 Study**  
**Session:** Innovative Drug Clinical Data Session 1  
**Date:** Thursday, September 19  
**Time:** 14:30 – 14:40  
**Location:** Strait Hall, Level 2  
**Presenter:** Yuqin Song, M.D., Ph.D., Beijing Cancer Hospital

**Title:** **Tislelizumab in Chinese Patients with Melanoma, Urothelial Carcinoma (UC), and Renal Cell Carcinoma (RCC)**  
**Session:** Kidney Cancer Session 4  
**Date:** Thursday, September 19



Time: 16:35 – 16:40  
Location Conference Room 2A, Level 2  
Presenter: Lili Mao, M.D., Ph.D. Beijing Cancer Hospital

**Title: Tislelizumab in Chinese Patients with Esophageal Cancer (EC), Gastric Cancer (GC), Hepatocellular Carcinoma (HCC), and Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Tumors**

Session: Advanced Gastric Cancer Session 3  
Date: Friday, September 20  
Time: 11:24 – 11:36  
Location Banquet Hall 1, Level 2  
Presenter: Lin Shen, M.D., Ph.D., Beijing Cancer Hospital

**Title: Safety and Efficacy in Patients with Long-Term Exposure (LTE) to Tislelizumab, an Investigational Anti-PD-1 Antibody, in a First-in-Human Phase 1 Study**

Session: Immuno-Oncology Session 3  
Date: Friday, September 20  
Time: 11:54 – 12:00  
Location Hall 1G, Level 1  
Presenter: Chia-Jui Yen, M.D., Ph.D., National Cheng Kung University Hospital

**Title: Tislelizumab Plus Chemotherapy as First-Line Treatment for Chinese Patients with Lung Cancer**

Session: Lung Cancer Session 3  
Date: Saturday, September 21  
Time: 11:38 – 11:44  
Location Auditorium, Level 1  
Presenter: Zhijie Wang, M.D., Ph.D., Cancer Hospital, Chinese Academy of Medical Sciences

**Title: Tislelizumab in Combination with Chemotherapy as**



**Treatment for Chinese Patients with Esophageal Squamous Cell Carcinoma (ESCC)**

Session: Innovative Drug Clinical Data Session 1  
Date: Saturday, September 21  
Time: 14:30 – 14:40  
Location: Banquet Hall 2, Level 2  
Presenter: Ru Jia, M.D., The Fifth Medical Center, General Hospital of the People's Liberation Army

**Poster Presentations:**

**Title: Dose Escalation of Pamiparib in Chinese Patients with High-Grade Non-Mucinous Ovarian Cancer (HGOC) or Advanced Triple-Negative Breast Cancer (TNBC)**

Board #: P-36  
Date: Thursday, September 19  
Time: Afternoon  
Location: Strait Hall Poster Area, Level 2  
Presenter: Xiyun Mu, M.D., BeiGene

**Title: Zanubrutinib for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma**

Board #: P-45  
Date: Friday, September 20  
Time: Morning  
Location: Strait Hall Poster Area, Level 2  
Presenter: Meng Ji, M.D., BeiGene

**Title: Zanubrutinib, a Highly Specific BTK Inhibitor in Chinese Patients with Relapsed/Refractory B-cell Malignancies: Follow-up Report of a Phase 1 Trial in China**

Board #: P-46  
Date: Friday, September 20  
Time: Morning



Location: Strait Hall Poster Area, Level 2  
Presenter: Chenmu Du, M.D., BeiGene

**Title: The molecular binding mechanism of tislelizumab, an investigational anti-PD-1 antibody, is differentiated from pembrolizumab and nivolumab**

Board #: P-60  
Date: Friday, September 20  
Time: Morning  
Location: Strait Hall Poster Area, Level 2  
Presenter: Ye Liu, Ph.D., BeiGene

### About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE<sup>®</sup> (nanoparticle albumin-bound paclitaxel), REVLIMID<sup>®</sup> (lenalidomide), and VIDAZA<sup>®</sup> (azacitidine) in China under a license from Celgene Corporation.<sup>1</sup>

### Investor Contact

Craig West  
+1 857-302-5189  
ir@beigene.com

### Media Contact

Liza Heapes  
+1 857-302-5663  
media@beigene.com

---

<sup>1</sup> ABRAXANE<sup>®</sup>, REVLIMID<sup>®</sup> and VIDAZA<sup>®</sup> are registered trademarks of Celgene Corporation.